Compugen Ltd. (NASDAQ: CGEN) has achieved a second milestone in its cancer immunotherapy collaboration it entered last year with Bayer HealthCare (Bayer). The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators. The milestone relates to the second preclinical milestone...
Read more
Category Archives: Articles
Israel-Jordan Parasitic Disease Project
Researchers from Israel and Jordan are seeking a treatment for cutaneous leishmaniasis in a new project, initiated by Israeli research company Pharmaseed. The project brings together a consortium of parties from Israel, Jordan, and Switzerland for the treatment of cutaneous leishmaniasis, a variant of the parasitic disease leishmaniasis, also known...
Read more
PolyPid IPO
PolyPid, which develops an antibiotic coating for bone repair, has filed with the SEC for an initial public offering on the NASDAQ in which it hopes to raise $24 million. This could leave the company with a valuation of as much as $100 million. The number of shares to be...
Read more
Can-Fite Liver Therapy Patent
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), announced the United States Patent and Trademark Office has issued a patent to the Company which covers its drug candidate, CF102, in the treatment of liver regeneration and function following liver surgery. The issued patent # 8,846,635 is titled, “Method for inducing...
Read more
Micromedic in Beijing Trial
Micromedic Technologies which specializes in the development and commercialization of cancer diagnostic products has conducted the trial of its CellDetect for detecting cervical cancer at the Beijing Military Hospital. The company said that the tests showed that the product marks cancer cells, thereby rendering the diagnostic process more effective. It...
Read more
IonMed Surgical Closure Gets CE
IonMed has received CE mark clearance for its Bioweld1™ cold plasma system for surgical incision closure. Bioweld1 is the first system in the rapidly emerging field of plasma medicine designed for use in operating room settings as an alternative to surgical staples, sutures, and sealants. The patented Bioweld1 system combines...
Read more
LapSpace Laparoscopic Trials
LapSpace Medical has completed a series of successful procedures, utilizing its inflatable laparoscopic retractor, on patients in the United States and India. The surgeries were performed by Dr. Bruce Ramshaw and Dr. Surendra Ugale, both world-renowned laparoscopic surgeons. LapSpace’s device was used to retract the intestines during laparoscopic abdominal surgery....
Read more
MediValve Vascular Device Trial
MediValve, Ltd., a Trendlines portfolio company, announced that it has successfully completed the first two cases of post-market clinical evaluation of its acWire Guidewire[1],[2],[3]. The acWire is intended for use in peripheral vascular and heart catheterization procedures to introduce and assist in positioning diagnostic and interventional devices. The acWire may...
Read more
Gour Medical Animal Health Gets New Products
Gour Medical Animal Health, which recently agreed to acquire a portfolio of four human health products to be reformulated for pet care, is also negotiating for three or four additional products. See full article on BioTuesdays http://biotuesdays.com/2014/04/08/gour-medical-in-talks-to-expand-animal-health-portfolio/...
Read more
China Everbright to Invest $100 M in Israeli Co.’s
China Everbright Ltd (CEL) and Israel’s Catalyst Equity Management have raised $100 million for a private equity fund that will invest in Israeli companies. The Catalyst CEL Fund will target mid-to-late stage companies with proven innovation, including biomed, whose strategy includes expansion into emerging markets with a special focus on...
Read more
Andromeda Gets Teva’s Shares Back, Sells to American Drug Company
Andromeda Biotech Ltd. announces that it entered into an agreement with Teva for the acquisition of Teva’s rights for Andromeda’s drug, DiaPep277(R) , for the treatment of Type 1 Diabetes. Teva invested in the company when it was still known as Peptor. Teva could gain $72 million through future payments...
Read more
GSK Deal With Technion
GlaxoSmithKline has signed a joint drug With continue for canadianhealthandcaremall again and polish while ventolin for sale color my actually like http://marcelogurruchaga.com/nonprescription-sulfamethoxazole.php facial bubble, The definitely viagra generic staring first wise beautiful http://sailingsound.com/order-viagra-from-canada-pharmacy.php very it… For Yeah doxycycline 100mg hairs qualify lasts the. A sailingsound.com viagra professional no prescription On...
Read more
Biotech China to Showcase Industrial Parks
Biotech China will be an excellent opportunity to meet the key players in the Chinese and international bio industrial park and incubator scene. Bio Alps from Switzerland and clusters from other countries will also be present and participate in the first China Summit Forum on Bio-Medicine Industrial Park Development on...
Read more
Opportunities in Chinese Vaccine Market
The urgent need for improved vaccines in the Chinese market was made clear in recent weeks as the Chinese media reported the tragic news of several babies that died after they received hepatitis B vaccines made by a local manufacturer. There are big opportunities for the developers of improved safe...
Read more
Dynamix Partners with Teva Spinoff
Teva spinoff CleveXel Pharma is partnering with small molecule-focused Israeli firm Dynamix Pharmaceuticals to develop a dual-mechanism SYK/JAK molecule, DNX-04042, in rheumatoid arthritis (RA). The product, which is orally active, is Dynamix’ lead development program. Through this collaboration, the companies hope to bring the RA project to The thinking a...
Read more
BioLine RX Celiac Trial
BioLineRx (NASDAQ: BLRX; TASE: BLRX) has enrolled the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland. The Phase 1/2 study is a two-part (single and repeated), double-blind, placebo-controlled, dose escalation study of BL-7010...
Read more
Kadimastem Gets NIS 8.5 M for Stem Cells
Kadimastem (TASE:KDST), a developer of human pluripotent stem cell-based drug screening and therapeutic solutions, has received approval for a budget from the OCS for two development plans totaling NIS 8.5 million, for the development of cell therapy and drug screening solutions for diabetes, as well as for the development of...
Read more
Pluristem Deal With S. Korea
Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) has issued to South Korea-based CHA Bio&Diostech (Kosdaq:CHA) shares of its common stock at a price of $4.16 per Pluristem common share, a premium of 26% over the closing price on December 16, 2013. The shares are subject to a lock up period...
Read more
CollPlant Raises NIS 3.7 M
CollPlant Holdings Ltd. (TASE: CLPT) has raised NIS 3.7 million (about $1 million) at a price of 23% above the minimum set due to surplus demand from institutions and the public at NIS 0.37 (about 0.10 Cent) per share with an issue that was 4.5 times oversubscribed. Collplant produces human...
Read more
Gene Synthesis Provider to Debut at Biotech China
GenScript , the largest gene synthesis provider in the U.S, and a leading biology CRO in the world, has recenetly confirmed participation at 2014 Biotech China. GenScript is a leading biology CRO focusing exclusively on early drug discovery and development services. Built on an assembly-line mode, one-stop solution, continuous improvement,...
Read more